- Home
- CMBT vs ARQT Comparison
CMBT vs ARQT Comparison
Compare CMBT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBT
- ARQT
- Stock Information
- Founded
- CMBT 1989
- ARQT 2016
- Country
- CMBT Belgium
- ARQT United States
- Employees
- CMBT N/A
- ARQT N/A
- Industry
- CMBT
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- CMBT
- ARQT Health Care
- Exchange
- CMBT NYSE
- ARQT Nasdaq
- Market Cap
- CMBT 1.9B
- ARQT 1.7B
- IPO Year
- CMBT N/A
- ARQT 2020
- Fundamental
- Price
- CMBT $9.33
- ARQT $14.86
- Analyst Decision
- CMBT
- ARQT Strong Buy
- Analyst Count
- CMBT 0
- ARQT 7
- Target Price
- CMBT N/A
- ARQT $18.67
- AVG Volume (30 Days)
- CMBT 91.2K
- ARQT 1.6M
- Earning Date
- CMBT 08-07-2025
- ARQT 08-06-2025
- Dividend Yield
- CMBT N/A
- ARQT N/A
- EPS Growth
- CMBT N/A
- ARQT N/A
- EPS
- CMBT 2.16
- ARQT N/A
- Revenue
- CMBT $934,913,000.00
- ARQT $212,819,000.00
- Revenue This Year
- CMBT $5.05
- ARQT $61.01
- Revenue Next Year
- CMBT $24.22
- ARQT $37.95
- P/E Ratio
- CMBT $4.32
- ARQT N/A
- Revenue Growth
- CMBT N/A
- ARQT 100.03
- 52 Week Low
- CMBT $7.65
- ARQT $7.86
- 52 Week High
- CMBT $18.43
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- CMBT 50.09
- ARQT 53.70
- Support Level
- CMBT $9.06
- ARQT $14.10
- Resistance Level
- CMBT $9.37
- ARQT $15.78
- Average True Range (ATR)
- CMBT 0.22
- ARQT 0.77
- MACD
- CMBT -0.01
- ARQT -0.02
- Stochastic Oscillator
- CMBT 36.49
- ARQT 57.82
About CMBT EURONAV
CMB.Tech NV owns and operates a fleet of vessels for international maritime shipping and storage of crude oil and petroleum products. It generate a large parts of their revenue from voyage charters, including vessels in pools that predominantly perform voyage charters. The company organizes itself into three divisons: the Marine division, the H2 Infra division and the H2 Industry division. The Marine Division derives maximum revenue.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.